An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
| Status: | Completed |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
| Start Date: | September 2005 |
| End Date: | March 2006 |
The purpose of this study is to predict responses to Erbitux as a single agent in patients
with Non Small Cell Lung Cancer
with Non Small Cell Lung Cancer
Inclusion Criteria:
- Measurable disease tumor available for biopsies
- Life expectancy of at least 3 months
Exclusion Criteria:
- Known or documented brain metastases prior to Cetuximab therapy
We found this trial at
1
site
Click here to add this to my saved trials
